SCHEMBL6795709

SCHEMBL6795709

Cc1ccnc(NC(=O)Cc2ccc(NC(=O)c3ccccc3-c3ccc(C(F)(F)F)cc3)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
RAB9A P51151 1/20 0.59
MAPK10 P53779 2/20 0.51
RIOK2 Q9BVS4 2/20 0.51
MAPK8 P45983 1/20 0.51
GSK3A P49840 1/20 0.51
HIPK1 Q86Z02 1/20 0.51
SNRK Q9NRH2 1/20 0.51
ALDH1A1 P00352 2/20 0.49
SORT1 Q99523 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MAPT P10636 1/20 0.48
POLB P06746 1/20 0.48
SMO Q99835 1/20 0.47
APOB P04114 4/20 0.47
MTTP P55157 4/20 0.47
CYP2D6 P10635 1/20 0.47
PSEN1 P49768 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799294 0.88 KMT2A (0.56) MEN1KMT2AALDH1A1SMN1; SMN2SMO
SCHEMBL6491755 0.87 KMT2A (0.50) MEN1KMT2ARAB9ASMOCYP2D6
SCHEMBL6913405 0.86 MEN1 (0.59) MEN1KMT2ARAB9AALDH1A1SMN1; SMN2
SCHEMBL6793184 0.84 KMT2A (0.58) KMT2ARAB9ASORT1SMN1; SMN2POLB
SCHEMBL6800838 0.84 SMO (0.53) ALDH1A1L3MBTL1SMOAPOBMTTP
SCHEMBL6797971 0.83 KMT2A (0.55) KMT2AL3MBTL1SMOAPOBMTTP
SCHEMBL6792355 0.81 KMT2A (0.59) MEN1KMT2ARAB9AALDH1A1SMN1; SMN2
SCHEMBL6794977 0.80 KDR (0.47) RIOK2ALDH1A1SMOAPOBMTTP
SCHEMBL6795297 0.80 SMO (0.53) MEN1KMT2ARIOK2ALDH1A1L3MBTL1
SCHEMBL6909836 0.80 WNT3A (0.58) RIOK2SMN1; SMN2MAPTSMOAPOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 MEN1 2426/4885KMT2A 2457/4885RAB9A 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.